Pharmion withdraws European thalidomide application

24 May 2004
News

Executive Summary

Pharmion withdraws its application for thalidomide in the treatment of multiple myeloma from the European Medicines Evaluation Agency, the company announces May 19. Pharmion said it will resubmit the application, which may allow for a broader label to include first line use. Pharmion partner Celgene has a thalidomide sNDA pending at FDA for use in multiple myeloma. Pharmion will evaluate whether Celgene's data is useful for European regulatory authorities...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS044040

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS044040

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Pharmion withdraws European thalidomide application

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert